ResultsIQ

ResultsIQ › Latest results › Morepen Laboratories Limited

Morepen Laboratories Limited Q4 FY25 earnings call summary

NSE: MOREPENLAB · BSE: 500288

Earnings call of 13 May 2025, summarised by AI from the filing.

Morepen FY25 revenue ₹1,830 cr, up 7.4%; management targets 10-15% growth for FY26 and FY27.

Key takeaways

  1. FY25 revenue Revenue ₹1,830 cr, up 7.4% from ₹1,704 cr, lower than expected 10-15% growth.
  2. Guidance Management working towards 10-15% company-level growth for FY26 and FY27.
  3. Q4 weakness Q4 FY25 EBITDA declined due to deferred U.S. and European export orders and non-repeat of a large order.
  4. Growth driver New molecules and formulations to drive growth; new products rose from ₹69 cr to ₹114 cr in four years.
  5. Risk API price drop of 24% over two years and China raw material price increases not yet accepted in India.

Original filing on BSE

Morepen Laboratories Limited Q1 FY27 results

As filed: Revenue ₹570 cr (+34% year on year), EBITDA ₹82.5 cr (+230% year on year), PAT ₹56.4 cr (+300% year on year), EBITDA margin 14.5% (+860 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹485 cr (+4% year on year), EBITDA ₹24.5 cr (−42% year on year), PAT ₹15.7 cr (−21% year on year), EBITDA margin 5.1% (−397 bps). Score 24 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 397 bps year on year. Other income 36% of PBT. Consolidated profit -21% but standalone +68%. Profit fell 43% from last quarter. Share price after the results: +21.0% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹484 cr (+7% year on year), EBITDA ₹46.3 cr (+29% year on year), PAT ₹27.5 cr (+2% year on year), EBITDA margin 9.6% (+162 bps). Score 46 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin rose 162 bps year on year. Profit fell 33% from last quarter. Share price after the results: +1.9% in 30 days (Nifty 500: −7.5%).
  • Q2 FY26: Revenue ₹412 cr (−6% year on year), EBITDA ₹30.0 cr (−32% year on year), PAT ₹41.0 cr (−57% year on year), EBITDA margin 7.3% (−276 bps). Score 17 of 100, Below trend. Revenue and profit before exceptional items growth were well below the company's own trend; EBITDA growth was below it. EBITDA margin fell 276 bps year on year. Tax rate 11%. Consolidated profit +17% but standalone -56%. Revenue fell 3% from last quarter. Share price after the results: −10.9% in 28 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹425 cr (−7% year on year), EBITDA ₹25.0 cr (−52% year on year), PAT ₹11.0 cr (−69% year on year), EBITDA margin 5.9% (−555 bps). Score 16 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 555 bps year on year. Revenue fell 9% from last quarter. Share price after the results: −12.8% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹466 cr (+10% year on year), EBITDA ₹42.0 cr (−14% year on year), PAT ₹20.0 cr (−29% year on year), EBITDA margin 9.0% (−257 bps). Score 29 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 257 bps year on year. Profit fell 26% from last quarter. Share price after the results: +11.6% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹453 cr (+2% year on year), EBITDA ₹36.0 cr (−28% year on year), PAT ₹27.0 cr (−16% year on year), EBITDA margin 8.0% (−329 bps). Score 13 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 329 bps year on year. Profit fell 23% from last quarter.
  • Q2 FY25: Revenue ₹438 cr (+4% year on year), EBITDA ₹44.0 cr (+29% year on year), PAT ₹35.0 cr (+67% year on year), EBITDA margin 10.1% (+199 bps). Score 68 of 100, Above trend. EBITDA margin rose 199 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 4% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Morepen Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.